Pharma Co. Slams Bid To Delay 'Orange Book' Delisting
By Kelly Lienhard · December 1, 2022, 4:59 PM EST
Avadel Pharmaceuticals criticized Jazz Pharmaceuticals' latest attempt to delay delisting of a patent that purportedly covers distribution of a narcolepsy drug from health regulators' so-called Orange Book, accusing Jazz of harming...
To view the full article, register now.